These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32950451)

  • 41. How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage.
    Izumiya Y; Hayashi H; Ishikawa H; Shibata A; Yoshiyama M
    Intern Med; 2021 Jan; 60(1):1-7. PubMed ID: 32713926
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnosis of cardiac transthyretin amyloidosis based on multimodality imaging.
    Dahlem K; Michels G; Kobe C; Bunck AC; Ten Freyhaus H; Pfister R
    Clin Res Cardiol; 2017 Jun; 106(6):471-473. PubMed ID: 28303323
    [No Abstract]   [Full Text] [Related]  

  • 43. The Truth Is Unfolding About Transthyretin Cardiac Amyloidosis.
    Grodin JL; Maurer MS
    Circulation; 2019 Jul; 140(1):27-30. PubMed ID: 31549879
    [No Abstract]   [Full Text] [Related]  

  • 44. Settling the Score With Cardiac Amyloidosis.
    Hanna M; Rosenthal JL
    JACC Cardiovasc Imaging; 2023 Dec; 16(12):1581-1583. PubMed ID: 37589608
    [No Abstract]   [Full Text] [Related]  

  • 45. Acute cardiac failure secondary to senile systemic amyloidosis.
    Bodard Q; Roca F; Dilly B; Laurent D; Chassagne P
    Age Ageing; 2016 Nov; 45(6):908-909. PubMed ID: 27103598
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of untyped cardiac amyloidosis by mass spectrometry in a patient with Gly6Ser transthyretin polymorphism in fatal cardiogenic shock.
    Damy T; Plante-Bordeneuve V; Dogan A
    Arch Cardiovasc Dis; 2014 Dec; 107(12):706-8. PubMed ID: 24070596
    [No Abstract]   [Full Text] [Related]  

  • 48. Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials.
    Cheng RK; Maurer MS
    JACC Heart Fail; 2021 Nov; 9(11):803-806. PubMed ID: 34509407
    [No Abstract]   [Full Text] [Related]  

  • 49. Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation.
    Tini G; Vianello PF; Gemelli C; Grandis M; Canepa M
    J Cardiovasc Transl Res; 2019 Dec; 12(6):514-516. PubMed ID: 30604309
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiac Involvement in a Patient Cohort With Val30Met Mutation Transthyretin Amyloidosis.
    Ripoll-Vera T; Buades J; Cisneros E; Gómez Y; Núñez J; Raya M
    Rev Esp Cardiol (Engl Ed); 2019 Jan; 72(1):92-94. PubMed ID: 29223374
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy.
    Hattori T; Takei Y; Koyama J; Nakazato M; Ikeda S
    Amyloid; 2003 Dec; 10(4):229-39. PubMed ID: 14986482
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Negative bone scintigraphy in wild-type transthyretin cardiac amyloidosis.
    Martini N; Rizzo S; Sarais C; Cipriani A
    BMC Cardiovasc Disord; 2020 Oct; 20(1):466. PubMed ID: 33121442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiac Amyloidosis: Mimics, Multimodality Imaging Diagnosis, and Treatment.
    Fazlinezhad A; Naqvi TZ
    JACC Cardiovasc Imaging; 2020 Jun; 13(6):1384-1391. PubMed ID: 32061555
    [No Abstract]   [Full Text] [Related]  

  • 54. Targeted Nuclear Imaging Probes for Cardiac Amyloidosis.
    Bravo PE; Dorbala S
    Curr Cardiol Rep; 2017 Jul; 19(7):59. PubMed ID: 28508350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amyloid cardiomyopathy.
    Kristen AV
    Herz; 2020 May; 45(3):267-271. PubMed ID: 32107564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Atrial impairment in transthyretin cardiac amyloidosis: an early marker of cardiac involvement and a prognostic factor.
    Di Bella G; Minutoli F
    Amyloid; 2018 Jun; 25(2):135. PubMed ID: 29523040
    [No Abstract]   [Full Text] [Related]  

  • 57. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center.
    López-Sainz Á; Hernandez-Hernandez A; Gonzalez-Lopez E; Domínguez F; Restrepo-Cordoba MA; Cobo-Marcos M; Gómez-Bueno M; Hernandez-Perez FJ; Oteo JF; Mirelis JG; Cavero MA; Moñivas V; Mingo Santos S; de Haro-Del Moral FJ; Krsnik I; Salas C; Bornstein B; Briceño A; López JA; Vázquez J; Alonso-Pulpón L; Segovia J; Garcia-Pavia P
    Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):149-158. PubMed ID: 32317158
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [State-of-the-art review on the non-invasive diagnosis approaches of patients with transthyretin cardiac amyloidosis].
    He S; Tian Z; Zhang SY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):276-279. PubMed ID: 32370477
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
    Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M
    J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.